170 related articles for article (PubMed ID: 3882856)
1. Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans.
Cryz SJ; Fürer E; Germanier R
J Infect Dis; 1985 Apr; 151(4):665-71. PubMed ID: 3882856
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans.
Cryz SJ; Mortimer P; Cross AS; Fürer E; Germanier R
Vaccine; 1986 Mar; 4(1):15-20. PubMed ID: 3962447
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered to victims of acute trauma.
Campbell WN; Hendrix E; Cryz S; Cross AS
Clin Infect Dis; 1996 Jul; 23(1):179-81. PubMed ID: 8816151
[TBL] [Abstract][Full Text] [Related]
4. Prevention of fatal experimental burn-wound sepsis due to Klebsiella pneumoniae KP1-O by immunization with homologous capsular polysaccharide.
Cryz SJ; Fürer E; Germanier R
J Infect Dis; 1984 Dec; 150(6):817-22. PubMed ID: 6389718
[TBL] [Abstract][Full Text] [Related]
5. Purification and vaccine potential of Klebsiella capsular polysaccharides.
Cryz SJ; Fürer E; Germanier R
Infect Immun; 1985 Oct; 50(1):225-30. PubMed ID: 4044036
[TBL] [Abstract][Full Text] [Related]
6. Capsular Polysaccharide Is Involved in NLRP3 Inflammasome Activation by Klebsiella pneumoniae Serotype K1.
Hua KF; Yang FL; Chiu HW; Chou JC; Dong WC; Lin CN; Lin CY; Wang JT; Li LH; Chiu HW; Chiu YC; Wu SH
Infect Immun; 2015 Sep; 83(9):3396-409. PubMed ID: 26077758
[TBL] [Abstract][Full Text] [Related]
7. Protection against fatal Klebsiella pneumoniae burn wound sepsis by passive transfer of anticapsular polysaccharide.
Cryz SJ; Fürer E; Germanier R
Infect Immun; 1984 Jul; 45(1):139-42. PubMed ID: 6376353
[TBL] [Abstract][Full Text] [Related]
8. Human IgG and IgA subclass response following immunization with a polyvalent Klebsiella capsular polysaccharide vaccine.
Cryz SJ; Cross AS; Sadoff GC; Que JU
Eur J Immunol; 1988 Dec; 18(12):2073-5. PubMed ID: 3220104
[TBL] [Abstract][Full Text] [Related]
9. Protection against fatal Klebsiella pneumoniae sepsis in the squirrel monkey Saimiri sciureus after immunization with a capsular polysaccharide vaccine.
Postal JM; Gysin J; Crenn Y
Ann Inst Pasteur Immunol; 1988; 139(4):401-7. PubMed ID: 3048318
[TBL] [Abstract][Full Text] [Related]
10. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.
Cryz SJ; Sadoff JC; Fürer E; Germanier R
J Infect Dis; 1986 Oct; 154(4):682-8. PubMed ID: 3091708
[TBL] [Abstract][Full Text] [Related]
11. Immunization against fatal experimental Klebsiella pneumoniae pneumonia.
Cryz SJ; Fürer E; Germanier R
Infect Immun; 1986 Nov; 54(2):403-7. PubMed ID: 3533779
[TBL] [Abstract][Full Text] [Related]
12. Development of
Lin TL; Yang FL; Ren CT; Pan YJ; Liao KS; Tu IF; Chang YP; Cheng YY; Wu CY; Wu SH; Wang JT
Front Immunol; 2022; 13():843183. PubMed ID: 35386691
[No Abstract] [Full Text] [Related]
13. Enzyme-linked immunosorbent assay to evaluate the immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans.
Granström M; Wretlind B; Markman B; Cryz S
J Clin Microbiol; 1988 Nov; 26(11):2257-61. PubMed ID: 3235653
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ELISA and RIA for measurement of pneumococcal antibodies before and after vaccination with 14-valent pneumococcal capsular polysaccharide vaccine.
Koskela M; Leinonen M
J Clin Pathol; 1981 Jan; 34(1):93-8. PubMed ID: 7007449
[TBL] [Abstract][Full Text] [Related]
15. Antibody response to pneumococcal vaccine in splenectomized children.
Pedersen FK
Acta Pathol Microbiol Immunol Scand C; 1983 Apr; 91(2):169-80. PubMed ID: 6880749
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults.
Kotloff KL; Fattom A; Basham L; Hawwari A; Harkonen S; Edelman R
Vaccine; 1996 Apr; 14(5):446-50. PubMed ID: 8735558
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of polysaccharides from type III, group B Streptococcus.
Baker CJ; Edwards MS; Kasper DL
J Clin Invest; 1978 Apr; 61(4):1107-10. PubMed ID: 96132
[TBL] [Abstract][Full Text] [Related]
18. Structural and biological insights into Klebsiella pneumoniae surface polysaccharide degradation by a bacteriophage K1 lyase: implications for clinical use.
Tu IF; Lin TL; Yang FL; Lee IM; Tu WL; Liao JH; Ko TP; Wu WJ; Jan JT; Ho MR; Chou CY; Wang AH; Wu CY; Wang JT; Huang KF; Wu SH
J Biomed Sci; 2022 Feb; 29(1):9. PubMed ID: 35130876
[TBL] [Abstract][Full Text] [Related]
19. Vaccination-induced circulation of human B cells secreting type-specific antibodies against pneumococcal polysaccharides.
Heilmann C; Henrichsen J; Pedersen FK
Scand J Immunol; 1987 Jan; 25(1):61-7. PubMed ID: 3492757
[TBL] [Abstract][Full Text] [Related]
20. A 5-year study of the seroepidemiology of Klebsiella pneumoniae: high prevalence of capsular serotype K1 in Taiwan and implication for vaccine efficacy.
Fung CP; Hu BS; Chang FY; Lee SC; Kuo BI; Ho M; Siu LK; Liu CY
J Infect Dis; 2000 Jun; 181(6):2075-9. PubMed ID: 10837197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
